CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
Chang-Wook Nam, Dong-Soo Kim, Jianyong Li, Marie T. Baccara-Dinet, Ivy Li, Ji-Hyun Kim, Chong-Jin Kim
Korean J Intern Med. 2019;34(6):1252-1262.   Published online 2018 September 1    DOI: https://doi.org/10.3904/kjim.2018.133

Excel Download

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
The Korean Journal of Internal Medicine. 2019;34(6):1252-1262   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
Clinical Cardiology. 2014;37(10):597-604   Crossref logo
Link1

Alirocumab in high cardiovascular risk patients with Heterozygous Familial Hypercholesterolemia: Efficacy and safety in lipid lowering levels
Nutrition, Metabolism and Cardiovascular Diseases. 2017;27(1):e11-e12   Crossref logo
Link1 Link2

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
American Heart Journal. 2015;169(6):906-915.e13   Crossref logo
Link1 Link2

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
BMC Cardiovascular Disorders. 2014;14(1):   Crossref logo
Link1 Link2 Link3 Link4

ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND WITH OR WITHOUT CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF 10 ODYSSEY RANDOMIZED TRIALS
Canadian Journal of Cardiology. 2017;33(10):S115-S116   Crossref logo
Link1 Link2

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
The American Journal of Cardiology. 2018;121(8):940-948   Crossref logo
Link1 Link2

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Atherosclerosis. 2016;244:138-146   Crossref logo
Link1 Link2

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
International Journal of Cardiology. 2016;223:750-757   Crossref logo
Link1 Link2

PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Cardiovascular Drugs and Therapy. 2016;30(5):427-431   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.